Annika Thorsell

Annika Thorsell

Auto-generated profile, based on publicly available information

Annika Thorsell

Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ATA. Thorsell
A. Thorsell
MMM. Michalkiewicz
M. Michalkiewicz
YDY. Dumont
Y. Dumont
RQR. Quirion
R. Quirion
LCL. Caberlotto
L. Caberlotto
MHM. Heilig
M. Heilig
Exogenous neuropeptide Y (NPY) reduces experimental anxiety in a wide range of animal models. The generation of an NPY-transgenic rat has provided a unique model to examine the role of endogenous NPY in control of stress and anxiety-related behaviors using paradigms previously used by pharmacological studies. Locomotor activity and baseline behavior on the elevated plus maze were normal in transgenic subjects. Two robust phenotypic traits were observed. ( i ) Transgenic subjects showed a markedly attenuated sensitivity to behavioral consequences of stress, in that they were insensitive to the normal anxiogenic-like effect of restraint stress on the elevated plus maze and displayed absent fear suppression of behavior in a punished drinking test. ( ii ) A selective impairment of spatial memory acquisition was found in the Morris water maze. Control experiments suggest these traits to be independent. These phenotypic traits were accompanied by an overexpression of prepro-NPY mRNA and NPY peptide and decreased NPY-Y1 binding within the hippocampus, a brain structure implicated both in memory processing and stress responses. Data obtained using this unique model support and extend a previously postulated anti-stress action of NPY and provide novel evidence for a role of NPY in learning and memory.

18 May 2010 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
VRV A Ramchandani
V A Ramchandani
JUJ Umhau
J Umhau
Francisco Javier Pavón MorónFrancisco Javier Pavón Morón
Francisco Javier Pavón Morón
VRV Ruiz-Velasco
V Ruiz-Velasco
WMW Margas
W Margas
MHM Heilig
M Heilig
Excessive alcohol use, a major cause of morbidity and mortality, is less well understood than other addictive disorders. Dopamine release in ventral striatum is a common element of drug reward, but alcohol has an unusually complex pharmacology, and humans vary greatly in their alcohol responses. This variation is related to genetic susceptibility for alcoholism, which contributes more than half of alcoholism risk. Here, we report that a functional OPRM1 A118G polymorphism is a major determinant of striatal dopamine responses to alcohol. Social drinkers recruited based on OPRM1 genotype were challenged in separate sessions with alcohol and placebo under pharmacokinetically controlled conditions, and examined for striatal dopamine release using positron emission tomography and [11C]-raclopride displacement. A striatal dopamine response to alcohol was restricted to carriers of the minor 118G allele. To directly establish the causal role of OPRM1 A118G variation, we generated two humanized mouse lines, carrying the respective human sequence variant. Brain microdialysis showed a fourfold greater peak dopamine response to an alcohol challenge in h/mOPRM1-118GG than in h/mOPRM1-118AA mice. OPRM1 A118G variation is a genetic determinant of dopamine responses to alcohol, a mechanism by which it likely modulates alcohol reward.

7 March 2007 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
DGDonald R. Gehlert
Donald R. Gehlert
ACAndrea Cippitelli
Andrea Cippitelli
ATAnnika Thorsell
Annika Thorsell
ALAnh Dzung Lê
Anh Dzung Lê
PHPhilip A. Hipskind
Philip A. Hipskind
MHMarkus Heilig
Markus Heilig
We describe a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with advantageous properties for clinical development, and itsin vivoactivity in preclinical alcoholism models. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine (MTIP) inhibited125I-sauvagine binding to rat pituitary membranes and cloned human CRF1with subnanomolar affinities, with no detectable activity at the CRF2receptor or other common drug targets. After oral administration to rats, MTIP inhibited125I-sauvagine binding to rat cerebellar membranesex vivowith an ED50of ∼1.3 mg/kg and an oral bioavailability of 91.1%. Compared with R121919 (2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a]pyrimidine) and CP154526 (N-butyl-N-ethyl-4,9-dimethyl-7-(2,4,6-trimethylphenyl)-3,5,7-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-2-amine), MTIP had a markedly reduced volume of distribution and clearance. Neither open-field activity nor baseline exploration of an elevated plus-maze was affected by MTIP (1–10 mg/kg). In contrast, MTIP dose-dependently reversed anxiogenic effects of withdrawal from a 3 g/kg alcohol dose. Similarly, MTIP blocked excessive alcohol self-administration in Wistar rats with a history of dependence, and in a genetic model of high alcohol preference, the msP rat, at doses that had no effect in nondependent Wistar rats. Also, MTIP blocked reinstatement of stress-induced alcohol seeking both in postdependent and in genetically selected msP animals, again at doses that were ineffective in nondependent Wistar rats. Based on these findings, MTIP is a promising candidate for treatment of alcohol dependence.

1 June 1997 in Brain Research
Verified
Journal Article
Closed access
CMChristian Möller
Christian Möller
LWLisa Wiklund
Lisa Wiklund
WSWolfgang Sommer
Wolfgang Sommer
ATAnnika Thorsell
Annika Thorsell
MHMarkus Heilig
Markus Heilig

14 March 2008 in Science
Verified
Journal Article
Closed access
PDF file
DGDavid T. George
David T. George
JGJodi Gilman
Jodi Gilman
JHJacqueline Hersh
Jacqueline Hersh
ATAnnika Thorsell
Annika Thorsell
DHDavid Herion
David Herion
MHMarkus Heilig
Markus Heilig
Alcohol dependence is a major public health challenge in need of new treatments. As alcoholism evolves, stress systems in the brain play an increasing role in motivating continued alcohol use and relapse. We investigated the role of the neurokinin 1 receptor (NK1R), a mediator of behavioral stress responses, in alcohol dependence and treatment. In preclinical studies, mice genetically deficient in NK1R showed a marked decrease in voluntary alcohol consumption and had an increased sensitivity to the sedative effects of alcohol. In a randomized controlled experimental study, we treated recently detoxified alcoholic inpatients with an NK1R antagonist (LY686017; n = 25) or placebo ( n = 25). LY686017 suppressed spontaneous alcohol cravings, improved overall well-being, blunted cravings induced by a challenge procedure, and attenuated concomitant cortisol responses. Brain functional magnetic resonance imaging responses to affective stimuli likewise suggested beneficial LY686017 effects. Thus, as assessed by these surrogate markers of efficacy, NK1R antagonism warrants further investigation as a treatment in alcoholism.

20 November 2014 in Neuropsychopharmacology
Verified
Journal Article
Closed access
LKLaura E Kwako
Laura E Kwako
PSPrimavera A Spagnolo
Primavera A Spagnolo
MSMelanie L Schwandt
Melanie L Schwandt
ATAnnika Thorsell
Annika Thorsell
DGDavid T George
David T George
MHMarkus Heilig
Markus Heilig